Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J, Wang G, Cheng H, Wei C, Qi K, Sang W, Zhenyu L, Shi M, Li H, Qiao J, Pan B, Zhao J, Wu Q, Zeng L, Niu M, Jing G, Zheng J, Xu K. Cao J, et al. Among authors: sang w. Am J Hematol. 2018 Jul;93(7):851-858. doi: 10.1002/ajh.25108. Epub 2018 Apr 28. Am J Hematol. 2018. PMID: 29633386 Free article.
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, Shi M, Lan J, Fei X, Jin L, Jing G, Sang W, Zhu F, Chen W, Wu Q, Yao Y, Wang G, Zhao J, Zheng J, Li Z, Xu K. Yan Z, et al. Among authors: sang w. Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1. Lancet Haematol. 2019. PMID: 31378662 Clinical Trial.
Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies.
Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J, Yan Z, Jing G, Pan B, Sang W, Li D, Wang X, Fu C, Zhu F, Zheng J, Li Z, Xu K. Wang Y, et al. Among authors: sang w. Biol Blood Marrow Transplant. 2020 May;26(5):865-875. doi: 10.1016/j.bbmt.2019.11.027. Epub 2019 Nov 28. Biol Blood Marrow Transplant. 2020. PMID: 31786240 Free article.
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, Yao M, Liu H, Li W, Zhang B, Sun K, Song X, Sun C, Jiao J, Qin Y, Sang T, Ma Y, Wu M, Gao X, Cheng H, Yan Z, Li D, Sun H, Zhu F, Wang Y, Zeng L, Li Z, Zheng J, Xu K. Sang W, et al. Among authors: sang t. Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1. Cancer Med. 2020. PMID: 32608579 Free PMC article. Clinical Trial.
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, Cheng H, Qiao J, Wang Y, Wang Y, Gao L, Shi M, Sang W, Zhu F, Li D, Sun H, Wu Q, Qi Y, Li H, Wang X, Li Z, Liu H, Zheng J, Qian W, Zhang X, Xu K. Yan Z, et al. Among authors: sang w. Front Immunol. 2021 Feb 23;12:611366. doi: 10.3389/fimmu.2021.611366. eCollection 2021. Front Immunol. 2021. PMID: 33708205 Free PMC article.
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
Chen W, Wang Y, Qi K, Shi M, Cao J, Bhansali R, Wang X, Liu Y, Li H, Zhang H, Yan Z, Sang W, Cheng H, Zhu F, Sun H, Li D, Jing G, Zheng J, Li Z, Xu K. Chen W, et al. Among authors: sang w. Transplant Cell Ther. 2021 Mar;27(3):273.e1-273.e5. doi: 10.1016/j.jtct.2020.12.017. Epub 2020 Dec 19. Transplant Cell Ther. 2021. PMID: 33781540 Free article. Clinical Trial.
468 results